secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0000950170-23-054508
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease
--------------------------------------------------------------------------------

- Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.
- Galecto will not initiate Part B of GALLANT-1, reallocating resources to severe liver diseases as part of strategic alternative process.
- Two severe dose-limiting skin reactions occurred at 200 mg dose; no such reactions at the recommended 100 mg dose level.
- Galecto to supply GB1211 for an investigator-initiated Phase 2 trial at Providence Portland Medical Center expected in early 2024.
- Company plans to explore external options for partnering/funding further oncology activities for GB1211.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/0000950170-23-054508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/glto-20231023.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-054508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer